Logo

Abbott and Dharmacon Announce siRNA Collaboration

Jul 29, 2003

NEW YORK, July 29  -- Abbott Laboratories and Dharmacon, of Lafayette, Colo.,  today announced a collaboration to develop a library of short-interfering RNA (siRNA) covering 4,000 genes to identify potential drug targets for therapeutics.

 

Financial details were not disclosed.

 

The siRNA library will be used in functional genomic studies designed to identify and validate drug targets for therapeutics for cancer, diabetes, pain management, inflammation, and neurological disorders.

Breaking News
The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.